Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 288

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 288
---
 particularly the conglomerates known as “chaebols”, are increasingly engaging in biotechnology investments and mergers and acquisitions (M&A) within the domestic and global healthcare markets. This trend is driven by a combination of strategic diversification, opportunities for growth, and a focus on innovative sectors with high potential. The BLAC Board and the BLAC M&A Committee identified such trends by the Korean corporate investors as an opportunity for OSR Holdings to transact with those corporate counterparties in Korea for potential licensing and/or M&A deals in the future. Below are some key aspects of how these companies are engaging in the biotech and healthcare sectors as discussed by the BLAC Board, BLAC M&A Committee and OSR Holdings management: 1)Strategic Investment •Direct Investments in Biotech Firms: Many Korean conglomerates are directly investing in biotech startups and established firms. These investments often focus on companies involved in cutting -edgeresearch, pharmaceuticals, medical devices, and digital health technologies. •Joint Ventures and Partnerships: Collaborating with both domestic and international biotech firms, Korean companies are forming joint ventures and partnerships to leverage their strengths and access new technologies. 171 2)Mergers and Acquisitions •Acquiring Biotech Firms: Korean companies are acquiring biotech firms to integrate new technologies, enhance their product portfolios, and enter new markets. These acquisitions often aim to strengthen capabilities in areas such as gene therapy, personalized medicine, and advanced diagnostics. •Global M&A Activities: The M&A activities are not confined to the domestic market. Korean firms are increasingly looking overseas to acquire companies with unique technologies and access to broader markets. The following are examples of notable transactions made by Korean corporate buyers in the global biopharmaceutical market, which the BLAC M&A Committee deemed relevant to its due diligence review. Samsung Biologics Acquisition of Biogen’s Stake in Samsung Bioepis (2022): Samsung Biologics acquired Biogen’s entire stake in Samsung Bioepis for approximately $2.3 billion, making it a wholly -ownedsubsidiary. This move was aimed at strengthening Samsung Biologics’ position in the biosimilars market and expanding its global footprint. SK Group Acquisition of AMPAC Fine Chemicals (2018): SK Holdings, part of the SK Group, acquired AMPAC Fine Chemicals, a U.S. -basedcontract development and manufacturing organization (CDMO). This acquisition was valued at around $700 million and aimed to bolster SK’s capabilities in pharmaceutical manufacturing.